A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45
Open Access
- 22 January 2009
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 100 (2), 366-369
- https://doi.org/10.1038/sj.bjc.6604839
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Trastuzumab — Mechanism of Action and Use in Clinical PracticeNew England Journal of Medicine, 2007
- Noxa Up-regulation and Mcl-1 Cleavage Are Associated to Apoptosis Induction by Bortezomib in Multiple MyelomaCancer Research, 2007
- CD45neg but Not CD45pos Human Myeloma Cells Are Sensitive to the Inhibition of IGF-1 Signaling by a Murine Anti-IGF-1R Monoclonal Antibody, mAVE1642Published by The American Association of Immunologists ,2006
- The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy.2006
- Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesisCancer Immunology, Immunotherapy, 2006
- Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With BortezomibJournal of Clinical Oncology, 2006
- Bortezomib: Proteasome Inhibition as an Effective Anticancer TherapyAnnual Review of Medicine, 2006
- CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity.2005
- Targeting tumor cellsCurrent Opinion in Cell Biology, 2003
- Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeuticsCancer Cell, 2002